Ask about this productRelated genes to: SARS NP antibody
- Gene:
- SARS NIH gene
- Name:
- seryl-tRNA synthetase
- Previous symbol:
- -
- Synonyms:
- SERS
- Chromosome:
- 1p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-06-09
- Date modifiied:
- 2014-11-18
- Gene:
- SARS2 NIH gene
- Name:
- seryl-tRNA synthetase 2, mitochondrial
- Previous symbol:
- SARSM
- Synonyms:
- FLJ20450, mtSerRS, SerRSmt, SARS, SERS, SYS
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-10-09
- Date modifiied:
- 2016-11-09
Related products to: SARS NP antibody
Related articles to: SARS NP antibody
- Preterm birth rates may have been affected during the COVID-19 pandemic but the impact of this on perinatal morbidity is unknown. - Source: PubMed
Publication date: 2026/05/02
Peart S RHaj-Yahya RNugent MGanbold OHarbinson LJly CheongManley B JWhitehead C L - Several families of viruses encode helicase enzymes with essential roles in viral genome replication and transcription, including several RNA virus families of pandemic concern, such as coronaviruses and flaviviruses. Viral helicases are widely considered to be promising antiviral targets with some DNA virus helicase inhibitors already approved for clinical use. Here, we demonstrate that the SARS-CoV-2 viral helicase, nsp13, is essential for viral replication. Using a previously developed in vitro helicase dsRNA unwinding assay, we screened 208 repurposed small molecules for nsp13 inhibition. Nine of these small molecules had a half-maximal inhibitory concentration (IC) less than 10 µM. These molecules were tested for in vitro inhibition of nsp13 ATPase activity as well as for inhibition of Yellow Fever Virus (YFV) NS3 helicase (NS3h) activity. FPA-124, a selective inhibitor of AKT kinase, was found to inhibit the unwinding activity of both SARS-CoV-2 nsp13 and YFV NS3h, though it only inhibited ATPase activity of nsp13. Molecular ligand docking confirmed that FPA-124 likely binds within the ATP binding pocket of nsp13, but not YFV NS3h. Unfortunately, FPA-124 had a low selective index in cultured lung cells, with an IC against SARS-CoV-2 near the half-maximal cytotoxic concentration (CC) in cells. Overall, we developed several high-throughput assays for antiviral drug screening against viral helicases and identified several lead scaffolds that may provide much needed tools to address future pandemics and endemic diseases with few treatment options. - Source: PubMed
Publication date: 2026/04/29
Inniss Nicole LRzhetskaya MargaritaKich Ryan PGleason ElizabethTaha Taha YZapatero-Belinchón Francisco JRosecrans JuliaPedrero-Classen ValentinaHuang KennethDegotte GillesLizzadro LucaPattie JasonRenslo Adam RMinasov GeorgeOtt MelanieBachta Kelly E RSatchell Karla J FHultquist Judd F - A simple method for enhanced detection of biological analytes is presented. It does not involve temperature cycling or temperatures above 37°C, can easily be integrated into existing protocols and requires only standard equipment. The procedure adds an extra amplification step to classical immunoassays. Oligonucleotide primers attached to antibodies are used for signal amplification and analyte detection. The oligonucleotides serve as primers in a reverse transcriptase (RT) reaction using a soluble complementary template and labeled nucleotides. The DNA strand synthesized is detected using the incorporated labels. Factors such as primer length, amount of labeled ligand, amount of RT activity, type of polymerase used, polymerase reaction time and temperature are explored and optimized to maximize the level of signal amplification. The capacity of the method is exemplified by a comparison between a standard capture ELISA for SARS-CoV-2 spike protein, and a polymerase amplified version of the same test. The increase in detection sensitivity achieved was approximately 70 times. - Source: PubMed
Publication date: 2026/04/29
Nordal VeronikaHedin JohannaPettersson JessicaMirzaei MaryamMalmsten AndersLarsson OlofStenlund PeterKällander Clas - The SARS-CoV-2 main protease (M, also known as 3CL) is an attractive antiviral drug target due to its essential role in viral replication and absence of human homologues. Development of new coronavirus-specific M inhibitors will be important as SARS-CoV-2 continues to evolve. Leveraging the rapidly expanding pool of diverse, experimental M-inhibitor data, we developed a target-specific deep learning workflow to accelerate the discovery of new M inhibitor compounds and fragment-like starting points. This workflow combined a fine-tuned inhibitor prediction model with solubility (logS) and lipophilicity (logP) models, molecular similarity analysis, and literature mining to prioritize novel, drug-like candidates. Applied to a purchasable library of over 500,000 compounds, the approach rapidly identified 24 candidates for experimental testing. Biochemical assays revealed a novel, small covalent inhibitor fragment (A02) with an apparent IC of 1.5 μM, prior to any synthetic optimization or derivatization. A 1.76 Å crystal structure of M bound to A02 confirmed covalent modification of the catalytic M cysteine (C145), unique engagement of the underutilized M S3' pocket, and the potential for derivatives of this scaffold to interact with additional M pockets in future optimization efforts. Together, these results demonstrate the potential for target-specific deep learning approaches to guide the rapid screening and discovery of new inhibitor leads or drug scaffolds. - Source: PubMed
Publication date: 2026/05/01
Zhou WeijunD Oliviera AngelDai XuhangMugridge Jeffrey SZhang Yingkai - Antigen-specific B cell profiling uncovers key determinants of SARS-CoV-2 antibody breadth after infection and vaccination. - Source: PubMed
Publication date: 2026/05/01
Ford Easton ESmith Melissa L